ALLMedicine™ Myasthenia Gravis Center
Research & Reviews 1,898 results
https://doi.org/10.1097/CJI.0000000000000422 10.1186/s12883-019-1416-1. 10.1093/omcr/omy094
Journal of Immunotherapy (Hagerstown, Md. : 1997); Dugena O, Zheng C et. al.
May 17th, 2022 - Immune checkpoint inhibition is a new and promising therapy approved for the treatment of various malignancies. Pembrolizumab is a potent tumor suppressor that acts by upregulating the immune system to recognize cancer cells which may result in di...
https://doi.org/10.1159/000524587
Journal of Innate Immunity; Gytz Olesen H, Michailidou I et. al.
May 14th, 2022 - Damage and disease of nerves activates the complement system. We demonstrated that activation of the terminal pathway of the complement system leads to the formation of the membrane attack complex (MAC) and delays regeneration in the peripheral ne...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097348
Journal of Cardiothoracic Surgery; Zhou RQ, Li LJ et. al.
May 14th, 2022 - Post-thymectomy myasthenia gravis (PTMG) is defined as thymoma patients without signs of myasthenia gravis (MG) pre-operation, but develop MG after radical surgical resection. PTMG might be misdiagnosed not only because of its rare incidence, but ...
https://clinicaltrials.gov/ct2/show/NCT04650854
May 13th, 2022 - The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).
https://doi.org/10.1136/practneurol-2022-003429
Practical Neurology; Alungulese AL, García Soldevilla MA et. al.
May 10th, 2022 - Oculopharyngeal muscular dystrophy (OPMD) and myasthenia gravis are both rare conditions of different pathophysiological nature, so a fortuitous association is unlikely. However, antiacetylcholine receptor antibodies may be found in other genetic ...
Guidelines 4 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105910
Journal of the Neurological Sciences; , Jacob S et. al.
Apr 5th, 2020 - Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.|2020| ,Jacob S,Muppidi S,Guidon A,Guptill J,|complications,drug therapy,epidemiology,therapeutic use,therapeutic use,t...
https://doi.org/10.1111/nyas.13503
Annals of the New York Academy of Sciences; Sussman J, Farrugia ME et. al.
Nov 10th, 2017 - Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to recei...
https://doi.org/10.1097/CCM.0000000000002027
Critical Care Medicine; Murray MJ, DeBlock H et. al.
Oct 19th, 2016 - To update the 2002 version of "Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient." A Task Force comprising 17 members of the Society of Critical Medicine with particular expertise in the use of n...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977114
Neurology Sanders DB, Wolfe GI et. al.
Jul 1st, 2016 - To develop formal consensus-based guidance for the management of myasthenia gravis (MG). In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international expe...
Drugs 55 results see all →
Clinicaltrials.gov 50 results
https://clinicaltrials.gov/ct2/show/NCT04650854
May 13th, 2022 - The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).
https://clinicaltrials.gov/ct2/show/NCT05358002
May 3rd, 2022 - - Population of study & disease condition: Congenital ptosis with poor levator muscle function. - Study setting: The ophthalmology unit of Abuelreesh Children Hospital. - Inclusion criteria: Criteria for inclusion in this study will be children mo...
https://clinicaltrials.gov/ct2/show/NCT05085288
May 3rd, 2022 - This is a two-arm, prospective randomized control trial assessing whether IES combined with the standard of care (treatment) is superior to the standard of care alone (control). The study is a parallel design, adaptive, non-blinded randomized cont...
https://clinicaltrials.gov/ct2/show/NCT05301153
May 3rd, 2022 - Follicular T cells play a vital role during autoimmune disorders. The enhanced number or activation of these cells results in hyperproliferation of autoreactive B cells and overproduction of antibodies. Interleukin-37 is a newly identified immune-...
https://clinicaltrials.gov/ct2/show/NCT05332587
May 2nd, 2022 - This study is designed to evaluate the effectiveness and safety of low-dose rituximab in patients with refractory myasthenia gravis. The traditional treatment of MG is immunosuppressive therapy, usually beginning with corticosteroids. However, up ...
News 141 results
https://www.medscape.com/viewarticle/974080
May 16th, 2022 - Two investigational medications are safe and effective for the treatment of generalized myasthenia gravis (gMG), new research shows. The phase 3 studies showed both zilucoplan and rozanolixizumab improve gMG-specific outcomes compared with placebo...
https://www.medpagetoday.com/infectiousdisease/covid19/98463
Apr 29th, 2022 - Note that some links may require registration or subscription. CDC confirmed the first human case of the H5N1 bird flu in the U.S., in a Colorado man with direct exposure to birds. Oklahoma Gov. Kevin Stitt (R) is expected to sign a "Texas-style" ...
https://www.medscape.com/viewarticle/970022
Mar 15th, 2022 - Myasthenia gravis (MG) is estimated to affect as many as 60,000 patients in the United States and more than 700,000 people worldwide. In approximately 10% of patients, complications can be life-threatening. However, with the right treatment, MG ca...
https://reference.medscape.com/viewarticle/970022
Mar 15th, 2022 - Myasthenia gravis (MG) is estimated to affect as many as 60,000 patients in the United States and more than 700,000 people worldwide. In approximately 10% of patients, complications can be life-threatening. However, with the right treatment, MG ca...
https://www.medscape.com/viewarticle/968599
Feb 16th, 2022 - Tens of thousands more people in the UK could be living with neuromuscular disease (NMD) than previous estimates suggested, according to new research. A study in the journal PLOS ONE, which analysed millions of GP records, suggested that the preva...